Baroness Hayman of Ullock (Lab)

My Lords, I thank noble Lords for their participation and questions in another short and sweet debate. The noble Baroness, Lady Grender, asked about the EU and divergence, and the noble Lord just touched on that as well. To clarify, this form of magnesium has been approved as a novel food in the EU, where it can be used in food supplements. There are some minor differences between the EU’s and the Food Standard Agency’s assessments, but they do not create a material difference or any safety concerns. In the FSA’s view, the differences are due to differences in assessment style rather than in the product itself. In addition, the applicant has confirmed that the product, as manufactured, will comply with both the EU and GB specifications. That therefore does not give rise to any concerns regarding its trade between GB and the EU. While we are on the EU, the noble Lord talked mainly about dynamic alignment and the legislation that will come with that, and asked for reassurances in that space. We are still in the middle of negotiations and I cannot go into the detail of them. They are not directly relevant to this statutory instrument, but the noble Lord knows that I am always more than happy to sit down, have a cup of tea and discuss these issues with him in detail as we move forward through the EU discussions. We know where we are on that. Just to finish, the noble Baroness also talked about review periods, safety, and so on within that. Clearly, a lot of these areas are in the FSA’s area, and we in Defra—and, I know, the Department of Health and Social Care—meet regularly with our colleagues in the Food Standards Agency, because it is really important that we uphold standards and work very closely together. I will reference these concerns in our next meeting with the FSA, because the noble Baroness makes very important points that when we are bringing in new legislation around novel foods, we need to ensure that we are confident in their safety for the long term and that consumers are being suitably protected. Having said all that, I remind noble Lords that this statutory instrument is very much a routine technical measure; it does not place any new burdens on businesses but ensures that use of the substance meets clear, consistent safety and quality standards. I thank noble Lords once again for their contributions and commend this SI to the Committee.